IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas by Duckworth, CA et al.
   
Page | 1  
 
IP1867B suppresses the Insulin-like Growth Factor 1 Receptor (IGF1R) ablating Epidermal Growth 
Factor Receptor inhibitor resistance in adult high grade gliomas. 
Mihajluk K1, Simms C1, Reay M1, Madureira P2. Howarth A1, Murray P1. Nasser S1, Duckworth 
CA3, Pritchard DM3, Pilkington GJ1 and Hill R1. 
1. Brain Tumour Research Centre, Institute of Biomedical and Biomolecular Sciences, IBBS, 
University of Portsmouth, PO1 2DT, UK. 
2. Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, 
Room 3.4, 8005-139 Faro, Portugal. 
3. Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University 
of Liverpool, L69 3GE, UK. 
 
Abstract 
High grade gliomas (HGGs) are aggressive primary brain tumours with local invasive growth and 
poor clinical prognosis. Clinical outcome is compounded by resistance to standard and novel 
therapeutics. We have evaluated reformulated aspirin (IP1867B) alone and in combination with 
conventional and novel anti-aHGG agents. We show that recent biopsy-derived aHGG models were 
highly resistant to conventional therapeutics although show sensitivity to IP1867B, a reformulated 
“liquid” aspirin. IP1867B treatment mediated a potent suppression of the IL6/STAT3 and NF-κB 
pathways and observed a significant reduction in EGFR transcription and protein expression. We 
observed the loss of the insulin-like growth factor 1 and insulin-like growth factor 1 receptor 
expression at both the transcript and protein level post IP1867B treatment. This increased sensitivity 
to EGFR inhibitors. In vivo, IP1867B was very well tolerated, had little-to-no gastric lesions versus 
aspirin and, directed a significant reduction of tumour burden with suppression of EGFR, IGF1 and 
IGFR1. With EGFR inhibitors, we noted a potent synergistic response in aHGG cells. These data 
provide a rationale for further investigation of IP1867B with a number of anti-EGFR agents 
currently being evaluated in the clinic. 
1. Introduction 
In 2017, 80,000 patients in the US and 11,400 in the UK were diagnosed with a primary brain 
tumour [1] [2]. Paediatric high grade glioma frequency in the US are 5.7 cases per 100,000. Adult 
HGG treatment comprises surgical resection and combined radio- and chemo-therapy [3,4]. The 
standard chemotherapeutic is temozolomide (TemodalTM) (TMZ), an oral DNA alkylating agent [5–
7]. TMZ and radiotherapy (the “Stupp protocol”) demonstrated significant patient survival benefit 
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versus radiotherapy alone, showing a median increase in survival of 2.5 months [3,4,8]. Cohort 
analysis revealed a discernible clinical response only in adult high grade glioma (aHGG) patients 
exhibiting promoter methylation of O6-methylguanine DNA methyltransferase (MGMT) [9]. 
Irrespective of MGMT promoter methylation, almost all aHGG patients exhibited eventual disease 
progression. An area that has attracted attention is the repurposing of Food and Drug 
Administration (FDA) approved agents for difficult-to-treat cancers, in particular high grade 
gliomas [10–12].  
Aspirin (acetylsalicylic acid, ASA) is a nonsteroidal anti-inflammatory drug which inhibits 
the cyclooxygenase (COX) enzymes COX-1 and COX-2 [13] and has been implicated in anti-
cancer responses [14]. Aspirin use post-diagnosis improved patient outcome, suggesting a role with 
conventional therapies [15]. The long-term use of aspirin reduced the cancer risk in paediatric 
patients with constitutional mismatch repair deficiency who are predisposed to cancer development 
[16]. There are over 20 registered clinical trials of aspirin for cancer therapy [17]. Aspirin solubility 
is low (1 g in: 300 mL water at 25OC) and there are serious concerns regarding gastrointestinal (GI) 
injury in patients prescribed aspirin long-term. Even low dose aspirin can induce duodenal mucosal 
injury including ulcers or haemorrhages.  
Approximately 50% of aHGG display EGFR amplification. Further, a number of aHGGs 
express a truncated EGFR (EGFRvIII) protein which is generated following the removal of exons 
2–7 [18,19] that displays constitutive, ligand-independent tyrosine kinase activity [20]. Insulin Like 
Growth Factor 1 Receptor (IGF1R) is rarely mutated or amplified in aHGG [21], where, activation 
of this network is considered ligand-dependant via endocrine mechanisms. IGF1R targeting has a 
significant impact on AKT signalling in aHGG [22], and is implicated in EGFR inhibitor resistance 
[23]. 
We report that IP1867B (ASA/triacetin/saccharin) directed a potent anti-aHGG response in 
vitro and in vivo. This was via suppression of the IL6/STAT3, NF-κB, IGF1/IGFR1 signalling 
networks. IP1867B exposure induced the down regulation of EGFR, at both protein and transcript 
level. IP1867B was well tolerated in non-neoplastic astrocytes and showed no associated in vivo GI 
toxicity. IP1867B synergised with EGFR inhibitors and in combination with IGF1R inhibitors had 
no additive effect.  
2. Materials and Methods. 
Tumour specimens and primary tumour cultures. Adult HGG biopsy samples were obtained 
from patients undergoing biopsy surgery at Kings College Hospital NHS Foundation Trust (LREC 
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review board (11/SC/0048) London, UK). Tumours were classified based on WHO criteria [1] after 
examination by neuro-pathologists. Tumour mass was mechanically dissociated into explant 
clumps, incubated at 37oC to allow neoplastic cells to colonize the flask/cell culture plates. Medium 
was changed every 2 days. When neoplastic cells reached confluence, cells were passaged and 
expanded. Once passage 1 cells were obtained, Short Tandem Repeat (STR) analysis was conducted 
to enable subsequent cell line authentication (Agilent Bioscience). 
Chemotherapeutics and Cell Culture. IP1867B (Innovate Pharmaceuticals), TMZ (T2577), 
vincristine (V0400000) and aspirin (Sigma-Aldrich). Gemcitabine (S1714), Gefitinib or AZD3759 
(SelleckChem). Adult glioma cell line U87MG was obtained from the ATCC and maintained in 
DMEM supplemented with 10% heat inactivated FCS (Sigma-Aldrich). Novel aHGG biopsy-lines 
UP-029, SEBTA-003, SEBTA-023 and SEBTA-025 were cultured in DMEM medium. CC2565 
non-neoplastic astrocytes (Lonza) were maintained in astrocyte growth medium supplemented with 
SingleQuots™ (CC-3187 Lonza) including (CC-4123): rhEGF, insulin, ascorbic acid, L-glutamine. 
Cells were cultured under normoxic (21%) or hypoxic (1%) O2 conditions. 
MTS cell viability assay. 5 x103 cells were seeded in triplicate in a 96 well plate. 24 hours post 
seeding, cell lines were treated with each agent. CellTiter 96® AQueous One Solution MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)) 
Reagent (G3580 Promega) was added and absorbance at 490nm recorded.  
Western blot analysis. Cells were harvested and lysed using RIPA buffer (89900, Thermo-Fisher) 
and 1x protease inhibitor cocktail (78442 Thermo-Fisher). 50 µg total protein was loaded per 
sample and separated by SDS-PAGE. Proteins were transferred onto PDVF membrane (BioRad). 
Membranes were blocked for 1 hour at room temperature (RT) in Odyssey blocking buffer (972-
46100 LICOR). Primary antibodies (Supplemental Table 1) were added overnight at 4°C. 
Secondary antibody were added (LICOR) at 1:10000 dilution for 1 hour at RT and membranes 
imaged on an Odyssey CLX (Licor). All uncropped immunoblots are shown in Supplemental 
Figures 1-5. 
Quantitative real time PCR. Total RNA was extracted (RNAeasy, 74104 Qiagen) and measured 
using RNA6000 chip (Agilent Bioscience, UK). 0.5 µg total RNA was used per cDNA synthesis 
reaction (iScript cDNA synthesis kit, 1708890 BioRad). Real Time PCR was performed using a 
LightCycler 96 (Roche) (iTaq SYBR Green, 1725120 BioRad). Primer sequences shown in 
supplemental Table 1. Data analysis was carried out using the 2-∆∆CT method [24]. 
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RT2 pathway transcriptomics and analysis. Total RNA was extracted per condition (NT, 6hr 
IP1867B) using the RNeasy Plus Mini Kit (Qiagen) including genomic DNA removal. The 
quantified by RNA 6000 Nano Kit (Agilent, UK). 0.5 µg of RNA was used for RT2 cDNA (Qiagen, 
UK). cDNA was added on the cell death Pathway Finder (PAHS-212Z), NF-κB signalling array 
(Qiagen, PAHS-025Z) and IL6/STAT3 signalling pathway (PAHS-160Z). Plates were run using a 
Light Cycler 96 (Roche, UK). The CT values were obtained and fold changes determined by 2-∆∆CT 
[24]. 
In vivo anti-tumour efficacy. 250,000 U87-luciferase cells were inoculated (intra-cranially) into 
NOD/SCID mice (aged 10-12 weeks). Animals were grouped based on luciferase imaging. 
Treatment was initiated every three days via IP injection, PBS, TMZ 50 mg/Kg/day or IP1867B 
30mg/Kg/day. In vivo bioluminescent imaging was performed once per week and all animals were 
weighed with behaviour and neurological signs (including altered gait, tremors, seizures and/or 
lethargy) monitored daily. This animal study was conducted with Institutional and Home Office 
ethical approval. 
In vivo gastric studies. Female C57BL/6 mice (aged 10-12 weeks, n=2-3 mice/group) were fasted 
for 16 hours and oral gavaged daily for 5 consecutive days with 1% methylcellulose (10 ml/kg), 
IP1867B (30 mg/kg) or aspirin (30 mg/kg). All animal studies were conducted with Home Office 
ethical approval. Stomachs were extracted and opened along their greater curvature and pinned to a 
bed of paraffin and formaldehyde fixed.   Stomachs were cut into strips containing antrum and 
corpus and processed for standard H&E staining.  Non-serial sectioned gastric mucosae were 
assessed for lesion number (521 ± 112 mm/stomach).  All animal studies were conducted with 
Institutional and Home Office ethical approval.  
Data analysis and statistics. Studies were analysed using GraphPad Prism and are represented as 
mean ± St.Dev. Statistical significance calculated using Student’s t-test, (*P ≤ 0.05), two-tailed 
ANOVA analysis, or the log-rank test for Kaplan Meier survival analyses. 
3. Results 
IP1867B demonstrates a potent in vitro anti-aHGG effect under both normoxic and hypoxic 
conditions.  
  We investigated how novel biopsy-derived aHGG responded to each excipient, IP1867B and 
temozolomide (TMZ) (Figure 1). 96 hours post drug treatment MTS viability assays were 
conducted and EC50 values determined (Figure 1A-D). Saccharin did not affect cell viability at even 
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the highest tested concentration of 36.5 mM. Triacetin significantly reduced cell viability although 
this was only at dosages >290 mM. When treated with aspirin alone, aHGG cells show limited cell 
death. The maximal solubility of aspirin (SIGMA Aldrich) was 3 mg/mL (16.65 mM). We were 
unable to dissolve aspirin at this concentration as significant particulate was observed. The highest 
concentration used was 1 mg/mL (5.55 mM).  Reduced aHGG cell viability was only observed at 
500 µM aspirin. We noted a significant reduction in aHGG cell viability following IP1867B 
treatment. Aspirin alone (SIGMA) and IP1867B noticeably changed the pH of the medium, 
consistent with high concentration acetylsalicylic acid. This alone did not account for the reduced 
cell viability as IP1867B significantly reduced aHGG cell viability at lower concentrations (Figure 
1).  
We determined the overall EC50 for each component and for TMZ (Figure 1E). Following a 
single treatment, IP1867B was significantly more potent compared to each agent and single dose 
TMZ exposure, a response conserved in a number of aHGG cell lines. The aHGG lines 
demonstrated high tolerance to single dose treatment with TMZ, particularly SEBTA-023, SEBTA-
003 and UP-029 that display unmethylated MGMT promoters. Representative microscopy images of 
each aHGG cell line 24 hour post IP1867B exposure revealed widespread cell death post-IP1867B 
treatment that was not observed post-treatment with any of the excipient components with only 
limited cell detachment/death post-TMZ treatment (Figure 1F). 
Adult HGG therapeutics need to be effective under both normoxic (21% O2) and hypoxic 
(1% O2) conditions. Cells were incubated under hypoxic conditions and treated with IP1867B. At 
96 hours MTS assays were conducted (under either hypoxic or normoxic conditions) and EC50 
concentrations determined for each (Figure 1G).  Irrespective of the environment, there was a 
significant reduction in cell viability post-IP1867B treatment. However, there was no significant 
difference between the EC50 values for each aHGG line cell under normoxic or hypoxic conditions 
post-IP1867B exposure.  
IP1867B formulation demonstrates synergy compared to each individual excipient component 
and increased the effectiveness of TMZ.  
 We questioned if the IP1867B formulation had a synergistic effect on treated aHGG cells. 
We determined the effective concentration for aspirin (SIGMA) (16 µM) and triacetin (0.6 mM) 
alone, an effective concentration for aspirin (SIGMA), triacetin and saccharin (the three excipients 
individually combined at 11 µM, 0.5 mM and 500 mM respectively) and finally for TMZ alone (9.1 
µM). Single/dual agents were added simultaneously and were compared to IP1867B (Figure 2A-D). 
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Treatment with aspirin (SIGMA) and TMZ was additive (where the TMZ EC50 fell between 6.1 - 
27.2 µM for each aHGG cell line). While there was a reduction in cell viability, this reduction was 
not statistically significant. When aspirin (SIGMA) and triacetin were used in combination to treat 
aHGG cells no significant change was noted. A potent synergistic response was observed when 
IP1867B was compared to each excipient component, or when the three individual components 
were independently combined (Figure 2E). When aspirin (SIGMA) and TMZ were used in 
combination, there was no significant difference in overall aHGG cell viability indicating that the 
combination of these in vitro did not have an additive effect (TMZ EC50 remained at 12.1 µM) 
(Figure 2F). IP1867B and TMZ when used together, showed an additive effect where the EC50 was 
≈0.5 µM (Figure 2G). We concluded that IP1867B was highly synergistic compared to each 
excipient component alone and while aspirin (SIGMA) and TMZ in combination did not 
significantly affect cell viability (either synergistic or additive), IP1867B and TMZ did have an 
additive response. We questioned if non-neoplastic cells were sensitive to IP1867B. Non-neoplastic 
CC2565 astrocytes were exposed to each individual component or to IP1867B (Figure 2H). At 96 
hours post IP1867B, CC2565 cells did not display a significant reduction in overall viability. 
IP1867B showed cancer-selectivity (EC50 concentration(s) for aHGG was between 0.39-0.6458 µM 
and the CC2565 EC50 was 10.16 µM) (P = 0.0038).   
IP1867B treatment induces the potent suppression of NF-κB and IGF1R 
We examined how IP1867B could mediate this response. We tested if there was significant 
caspase 3 cleavage following treatment with the IP1867B (Figure 3A). There was the significant 
detection of cleaved caspase 3 at 96 hours post-treatment. We questioned if there was p53 
accumulation and activation. We did not see discernible p53 accumulation although noted p53 
phosphorylation (Ser15 and Ser46) (Figure 3B). In SEBTA-023 aHGG cells we were unable to 
detect any p53. To complement this study, each aHGG cell line was exposed to IP1867B or TMZ 
(100 µM) and at 24 and 96 hours post treatment FACS analysis was conducted (Figure 3C). We 
detected significant accumulation of asub-G1 cell population consistent with cell death post 
IP1867B treatment. At 96 hour post-treatment, TMZ exposure also increased the sub-G1 cell 
population, however this was significantly lower compared to IP1867B treated aHGG cells. 
We evaluated the aHGG transcription response post IP1867B exposure and examined a 
diverse range of cell death networks, the NF-κB pathway, and the inflammation response (Figure 
3D, E and F). Three housekeeping genes Beta-2-microglobulin (B2M), hypoxanthine 
phosphoribosyltransferase 1 (HRPT1) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
were used for data normalization, and the fold change for each gene of interest was calculated. 12 
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hours post IP1867B treatment, we noted a significant down regulation of various pro-inflammatory 
genes including interlukin (IL)12A, IL18, IL4, IL5, IL6, IL6-receptor, tumour necrosis factor (TNF), 
TNF-receptor 1A and TNF-receptor 11B (Figure 3G). When treated with IP1867B, aHGG cells 
directed a significant transcription increase in IL11. IL6 drives many of cancer hallmarks via the 
downstream activation of STAT3. IL11 has been shown to direct a more prominent role compared 
to IL6 in inflammation associated cancers, suggesting a potential compensatory mechanism directed 
by aHGG following IP1867B exposure [25]. These data raise the hypothesis that IP1867B could 
significantly complement a number of IL11 inhibitors (such as Bazedoxifene and mIL-11 Mutein) 
currently being tested in various gastrointestinal and breast cancers [25–27]. 
The related genes Insulin-like growth factor 1 (IGF1) and Insulin-like growth factor 1 
receptor (IGF1R) were identified by our analysis post-IP1867B treatment (Figure 3G). IGF1 and 
IGF1R both showed a highly significant expression decrease of 9.42 and 7.39 fold versus untreated 
aHGG cells respectively. IGF1 and IGF1R can confer chemo-resistance and have been considered 
important for EGFR inhibitor resistance [28]. These data suggested that IP1867B could 
significantly inhibit IGF1 and IGF1R by potently reducing their expression and may, sensitise 
aHGGs to these therapeutics.  Following IP1867B treatment, we noted subtle, although statistically 
significant, increases in caspase 3, caspase 6 and caspase 9 expression supporting the induction of 
apoptosis (Figure 3G). We observed the direct repression of EGFR (2.73 fold reduction) post-
IP1867B treatment of UP-029 aHGG cells. These aHGG lines showed significant EGFR over 
expression and suggested a second mechanism where IP1867B could significantly enhance the 
effectiveness of aHGG therapeutics, in particular EGFR inhibitors supported by IL4 and IL6 
repression. 
We broadened our findings and included additional, recent biopsy-derived aHGG cell lines 
(Figure 4A, B and C). IP1867B directed an anti-inflammatory transcription response, characterized 
by the repression of IL6, IL6-receptor, TNF, TNF-receptor 1A and the significant induction of IL11. 
There was a significant reduction of EGFR, IGF1 and IGF1R transcription. We questioned if these 
transcriptional data were conserved at the protein level and noted that there was a considerable 
reduction of IGF1R, IL6R and EGFR protein expression post-IP1867B treatment in our aHGG cells 
(Figure 4D). These data raised the interesting hypothesis that IP1867B treatment could complement 
EGFR inhibitors.  We treated our aHGG cell lines with Gefitinib (EC50 5µM/L), AZD3759 (EC50 
50 nM) alone or in combination with IP1867B (Figure 4E and 4F). Adult HGG cells showed limited 
sensitivity to Gefitinib and AZD3759 however, when used in combination with IP1867B, there was 
a significant increase in sensitivity to each agent. Each inhibitor was effective as a significant loss 
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of detectable pY1068-EGFR was noted following exposure with Gefitnib and AZD3759 (Figure 
4G). EGFRvIII has been shown to be a direct regulator of STAT3. It was compelling that IP1867B 
treatment supressed this response [29]. IP1867B treatment in UP-029 and SEBTA-023 aHGG cells 
triggered a reduction in this network although we still detected, albeit reduced, EGFR and pY1068-
EGFR. In untreated, Gefitinib, or AZD3759, treated aHGG cells, there was robust detection of 
IGF1R. Post-IP1867B treatment there was a significant reduction of IGF1R protein expression. The 
IGF1R pathway is an important receptor tyrosine kinase (RTK) in aHGG tumours [23]. In aHGG 
cells with high IGF1R expression, we detected high levels of pSer473 AKT (Figure 4G). Neither 
Gefitinib nor AZD3759 had a significant impact on pSer473 AKT level, although IP1867B 
treatment noticeably reduced the level of pSer473 AKT. Concomitantly, we noted elevated 
FOXO3a-dependent gene expression post-IP1867B treatment (Figure 4H). These data indicated that 
there was significant suppression of the inflammation response and the IGF1R network, including 
AKT, which together increased the effectiveness of EGFR inhibitors.  
IP1867B effectively repressed aHGG growth in intracranial implanted tumours. 
The in vivo effectiveness of IP1867B was addressed using a U87-luciferase model. U87-
MG-luciferase aHGG cells were intracranially implanted into NOD/SCID mice (six mice per group) 
and 7 days post-inoculation, luciferase activity was measured. Tumour-bearing mice were treated 
on day 1, 3, 5, 8, 10 and 12 by intraperitoneal (IP) injection of vehicle, IP1867B (30 mg/kg) or 
TMZ (50 mg/kg) (Figure 5A). There was a significant reduction in luciferase expression in 
IP1867B treated mice and a significant increase in survival (Figure 5B). We collected the brain and 
liver of each animal. We noted significant intracranial tumour in vehicle treated mice, in particular, 
gross disruption of brain architecture and disruption of the midline. TMZ and IP1867B treated 
brains showed “normal” brain structure (Figure 5C). We carefully monitored animal weight and 
behaviour and noted there was no significant weight loss in IP1867B treatment group (Figure 5D). 
A concern regarding high dose aspirin treatment was potential damage and lesion development 
within the gastrointestinal tract. In an independent (non-tumour bearing mouse study) we examined 
if IP1867B oral administration induced any gastric mucosal lesions (Figure 5E). There were 
significantly less total mucosal membrane lesions in addition to significantly reduced lesion 
frequency (per mm) in IP1867B treated mice versus aspirin treated mice (Figure 5F).  
IP1867B treatment of tumour bearing mice significantly reduced IGF1 and IGF1R in vivo 
expression and, in agreement with our in vitro data, there was a significant down regulation of 
multiple inflammatory genes in the treated tumours (Figure 5G and 5H). There was an upregulation 
of caspase 3 and caspase 9 transcription in the IP1867B treated mice brains although this induction 
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was not seen in the matched livers (data not shown). A number of apoptotic markers were 
upregulated in the brains and livers of TMZ treated mice. This was both tumour specific (as 
measured using human-specific primers) and systemic (determined using mouse specific primers). 
Following IP1867B exposure, there was a significant downregulation of EGFR protein expression 
in the tumours of treated mice (Figure 5I). This downregulation was not observed following mock 
or TMZ treatment regimens. 
4. Discussion 
The gold standard treatment for aHGG patients is the “Stupp protocol” with temozolomide. 
Despite this aggressive multi-modal regimen, patient prognosis remains poor with median survival 
of approximately 15 months. 
The nonsteroidal anti-inflammatory agent aspirin is widely used for preventing and treating 
cardiovascular and cerebrovascular diseases while recent cohort analysis has suggested that aspirin 
may prevent a range of cancers (including colon, gastric and pancreatic cancer) [30–33]. There is 
accumulating evidence that aspirin may act in different cell types, including epithelial cells, tumour 
cells, endothelial cells, platelet, and immune cells. Consequently, aspirin could act on multiple 
cancer hallmarks including cell growth, metastasis, angiogenesis and inflammation. There are noted 
side effects during long-term low dose aspirin treatment regimens that include nausea, vomiting, 
and abdominal pain. An important clinical complication following long-term aspirin administration 
is gastrointestinal injury, in particular gastroduodenal destruction, ulceration, and haemorrhage(s) 
[34].  The risk of major bleeding following aspirin treatment is higher in patients aged 75 years or 
older [34]. The median age at diagnosis of aHGG is 64 [35,36] where the incidence increases with 
age peaking between 75–84 years and this could present a major clinical obstacle for standard 
aspirin to be considered as a preventative or combinational therapy for aHGG patients. 
Here we evaluated, IP1867B, a “true liquid” aspirin formulation. IP1867B allowed a higher 
concentration of ASA to be delivered in vitro, directed a potent anti-aHGG response and was well 
tolerated by non-neoplastic astrocytes. Compared to each excipient component, IP1867B was 
synergistic and directed a potent anti-aHGG response independent of MGMT promoter methylation. 
There was induction of apoptosis following IP1867B treatment, consistent with caspase 3 cleavage. 
One of our biopsy-derived aHGG cells had no detectable p53 protein although was sensitive to 
IP1867B, suggesting that the mechanism of action was likely p53-independent. There was 
significant suppression of the NF-κB and IL6/STAT3 pathways and in particular suppression of 
EGFR transcription post-IP1867B exposure. We validated the suppression of EGFR transcription 
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and noted the concomitant reduction of EGFR protein expression. A number of anti-EGFR clinical 
trials have been instigated and for aHGG [37,38]. Our data suggested that IP1867B could 
complement EGFR inhibitors. We evaluated Getfinib and AZD3759 alone and in combination with 
IP1867B. Dual treatment with IP1867B significantly increased the potency of two EGFR inhibitors 
and significantly reduced ser473-AKT phosphorylation in two in vitro aHGG models. We examined 
the transcription of IGF1 and IGF1R as these have been implicated in EGFR signalling and could 
inhibit AKT activation. IP1867B treatment significantly reduced IGF1 and IGF1R transcription. 
These data were highly unexpected and compelling as to date there are no blood-brain barrier 
permissive anti-IGF1 and IGF1R treatments. Metabolic complications such as obesity, 
hyperglycemia, and type 2 diabetes are associated with poor outcomes in aHGG patients. To control 
peritumoral edema, high-dose steroids usage is common which can result in de novo diabetic 
symptoms. These could activate IGF1 and IGF1R in aHGG cells. The administration of IP1867B 
could significantly attenuate these treatment complications noted in aHGG patients.  
IP1867B showed discernibly less propensity in producing gastric injury and induced 
significantly less gastric mucosal lesions compared to conventional aspirin.  There was no 
significant difference between vehicle and IP1867B treated mice. The IP administration of IP1867B 
caused a significant reduction in overall intracranial tumour mass and was well tolerated. Tumour-
bearing mice showed no significant weight loss or behavioural changes indicative of tumour 
burden. Both in vitro and in vivo IP1867B treatment revealed a reduction of EGFR in addition to 
reduced IGF1 and IGF1R expression.  
These data warrant follow-up in combination with EGFR inhibitors and validation of 
1P1867B as a putative IGF1 and IGF1R inhibitor. Care is required as IGF1 and IGF1R have 
important functions in metabolism thus the prolonged blockade of this pathway may be associated 
with adverse effects. Agents that can penetrate the blood-brain barrier and complement 
conventional and novel therapeutics are of significant interest and warrant follow-up investigation.  
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